Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO™
SAN DIEGO, May 20, 2016 -- Otonomy, Inc. (OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through status and established a new billing code for OTIPRIO™ (ciprofloxacin otic suspension). The code, C9479, will become effective July 1, 2016.
“We welcome CMS’s decision to grant pass-through status and assign a new C code for OTIPRIO which can be used for billing in the hospital outpatient and ambulatory surgery center (ASC) settings,” said David A. Weber, Ph.D., president and CEO of Otonomy. “Furthermore, the timing of this assignment early in the launch of OTIPRIO will, we believe, be very helpful in our ongoing efforts to facilitate patient access.”
According to a CMS reference article, “C codes are unique temporary pricing codes that were initially established by CMS for the Hospital Outpatient Prospective Payment System (OPPS).
- Published: 20 May 2016
- Written by Editor
Terraco to Exercise Spring Valley Royalties and Enters Into US$19,030,000 Strategic Transaction
Oban Intersects 17.22 g/t Au Over 3.9 Metres at Windfall
Histogenics Corporation Announces First Quarter 2016 Financial and Operating Results
NexGen Energy Ltd. - Hole AR-16-76c1 Returns 67.5 m at 11.29% U3O8 including 9.0 m at 51.35% U3O8 and 0.5 m at 79.80% U3O8
